VEGF-B promotes cancer metastasis through a VEGF-A–independent mechanism and serves as a marker of poor prognosis for cancer patients
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Significance: Cancer metastasis is responsible for a majority of the mortality in cancer patients and involves complex interactions, modulated by various factors and cytokines, between malignant and host cells. Vascular structures in solid tumors are crucial for cancer cell intravasation into the circulation. Our present work shows that VEGF-B produced by tumor cells significantly remodels tumor microvasculature, leading to leaky vascular networks that are highly permissive for tumor cell invasion. VEGF-B–promoted cancer metastasis occurs through a VEGF-A–independent mechanism. Thus, inhibition of VEGF-B should be considered an independent approach for the development of new drugs for the treatment of cancer invasion and metastasis. VEGF-B also may be considered as an independent prognostic marker for cancer metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“For example, the tumor vasculature is essential for tumor growth and metastasis (2), and blocking tumor angiogenesis has been used successfully for treatment of animal and human cancers (3–5).”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Paradoxically, anti–VEGF-A drugs such as bevacizumab also have been claimed to induce normalized vasculatures with reduced vascular permeability (28, 32).”
BackgroundVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247 · cited 1×
“Again, circulating tumor cells interact closely with endothelial cells and perivascular cells to manipulate vascular structures for extravasation (10).”
BackgroundTumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“Among all known angiogenic factors, vascular endothelial growth factor A (VEGF-A), which modulates angiogenesis, vascular permeability, vessel survival, and vascular remodeling, is probably the best characterized (13, 14).”
BackgroundMicroenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 1×
“Among all known angiogenic factors, vascular endothelial growth factor A (VEGF-A), which modulates angiogenesis, vascular permeability, vessel survival, and vascular remodeling, is probably the best characterized (13, 14).”
BackgroundTumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367 · cited 13×
“(F, Left) FACS analysis of CTCs in mice bearing vectorand VEGF-B-528ras tumors.”
BackgroundInfluentialTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
In Vivo Imaging of Embryonic Vascular Development Using Transgenic Zebrafish
Lawson, N. D., & Weinstein, B. M. (2002) · Developmental Biology · doi:10.1006/dbio.2002.0711 · Cited by 2,151 · cited 1×
“The relation between disseminated tumor cells and vasculature was investigated using the transgenic Fli1:EGFP zebrafish strain (25).”
BackgroundThe metastatic niche: adapting the foreign soil
Psaila, B., & Lyden, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2621 · Cited by 1,300
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., & Shibuya, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9349 · Cited by 1,062 · cited 14×
“Interestingly, both PlGF and VEGF-B bind to VEGFR1, but they display opposing effects in remodeling tumor vessels.”
MethodInfluentialVascular endothelial growth factor B, a novel growth factor for endothelial cells.
Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V, Saksela, O., Orpana, A., Pettersson, R. F., Alitalo, K., & Eriksson, U. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2576 · Cited by 803 · cited 2×
“Despite its early discovery, the biological functions, and especially the vascular functions, of VEGF-B remain an enigma (18, 19).”
BackgroundAnti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705
Self-citationEphrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker-Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 534 · cited 1×
“Although VEGF-A binds to VEGF receptor 1 (VEGFR1) and VEGFR2, two tyrosine kinase receptors, it is believed that VEGFR2 mediates most of these VEGF-A–triggered vascular functions (15).”
BackgroundHIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483
Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis
Shibuya, M. (2006) · Angiogenesis · doi:10.1007/s10456-006-9055-8 · Cited by 437 · cited 1×
“Unlike VEGF-A, VEGF-B binds only to VEGFR1, which also is considered a decoy receptor that transduces negative signals for angiogenesis (16, 17).”
BackgroundZhang, F., Tang, Z., Hou, X., Lennartsson, J., Li, Y., Koch, A. W., Scotney, P., Lee, C., Arjunan, P., Dong, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813061106 · Cited by 307 · cited 1×
“However, later studies do not support these claims, and opposing results that VEGF-B inhibits tumor angiogenesis have been reported (20, 21).”
ResultSelf-citationPositive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Cao, Y. (2009) · Science Signaling · doi:10.1126/scisignal.259re1 · Cited by 289 · cited 2×
“Through which receptor does VEGF-B promote cancer metastasis? Would neuropilin1 (NRP1) be a potential receptor for these effects? If so, why do other NRP1-binding ligands such as PlGF not produce vascular remodeling and metastatic effects similar to those of VEGF-B? VEGF-B and PlGF are the two most structurally and fu…”
BackgroundSelf-citationVascular endothelial grouth facter B, a novel growth facter for endothelial cells
Olffson, B. (1996) · Medical Entomology and Zoology · Cited by 279
Lee, S. L. C., Rouhi, P., Jensen, L. D., Zhang, D., Ji, H., Hauptmann, G., Ingham, P., & Cao, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909228106 · Cited by 240
Self-citationForty-Year Journey of Angiogenesis Translational Research
Cao, Y., Arbiser, J., D’Amato, R. J., D’Amore, P. A., Ingber, D. E., Kerbel, R., Klagsbrun, M., Lim, S., Moses, M. A., Zetter, B., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003149 · Cited by 223
Self-citationEriksson, A., Cao, R., Pawliuk, R., Berg, S.-M., Tsang, M., Zhou, D., Fleet, C., Tritsaris, K., Dissing, S., Leboulch, P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00028-4 · Cited by 198
Self-citationJubb, A. M., Pham, T. Q., Hanby, A. M., Frantz, G. D., Peale, F. V., Wu, T. D., Koeppen, H. W., & Hillan, K. J. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.012963 · Cited by 163 · cited 1×
“Tumors often express angiogenic factors at high levels to induce neovascularization (11).”
BackgroundAnti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues
Yang, Y., Zhang, Y., Cao, Z., Ji, H., Yang, X., Iwamoto, H., Wahlberg, E., Länne, T., Sun, B., & Cao, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301331110 · Cited by 139
Self-citationHypoxia-induced metastasis model in embryonic zebrafish
Rouhi, P., Jensen, L. D., Cao, Z., Hosaka, K., Länne, T., Wahlberg, E., Steffensen, J. F., & Cao, Y. (2010) · Nature Protocols · doi:10.1038/nprot.2010.150 · Cited by 136
Self-citationMunson, J. M., Fried, L., Rowson, S. A., Bonner, M. Y., Karumbaiah, L., Diaz, B., Courtneidge, S. A., Knaus, U. G., Brat, D. J., Arbiser, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003016 · Cited by 112 · cited 1×
“Proc Natl Acad Sci USA 106(43):18408–18413.”
VEGF-B: A survival, or an angiogenic factor?
Li, X., Lee, C., Tang, Z., Zhang, F., Arjunan, P., Li, Y., Hou, X., Kumar, A., & Dong, L. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.4.9459 · Cited by 112
Optimizing the Delivery of Cancer Drugs That Block Angiogenesis
Cao, Y., & Langer, R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000399 · Cited by 90 · cited 2×
“Angiogenesis 9(4):225–230, discussion 231.”
BackgroundSelf-citationXu, L., Cochran, D., Tong, R. T., Winkler, F., Kashiwagi, S., Jain, R. K., & Fukumura, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-3085 · Cited by 89 · cited 1×
“Proc Natl Acad Sci USA 110(34):13932–13937.”
Bonner, M. Y., & Arbiser, J. L. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.86 · Cited by 89
Therapeutic Targets of Multiple Angiogenic Factors for the Treatment of Cancer and Metastasis
Cao, Y., & Liu, Q. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97009-2 · Cited by 76 · cited 1×
“Multiple growth factors/cytokines and their signaling receptors often coexist in the same tumor microenvironment and collectively modulate tumor growth, invasiveness and metastasis (12).”
BackgroundSelf-citationYang, X., Zhang, Y., Yang, Y., Lim, S., Cao, Z., Rak, J. W., & Cao, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309629110 · Cited by 74 · cited 2×
“Placental growth factor (PlGF), another member of the VEGF family closely related to VEGF-B, also remodels tumor vasculature toward a normalized phenotype through a VEGF-A–dependent mechanism of spatiotemporal vascular regulation (28, 29).”
BackgroundSelf-citationViloria‐Petit, A., Miquerol, L., Yu, J. L., Gertsenstein, M., Sheehan, C., May, L., Henkin, J., Lobe, C., Nagy, A., Kerbel, R. S., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg408 · Cited by 71 · cited 1×
“To investigate the relation between VEGF-B and VEGF-A in tumor angiogenesis and metastasis, we used a VEGF-A–null tumor cell line (528ras) that was generated from Vegfamouse embryonic fibroblasts (26).”
MethodDahl Ejby Jensen, L., Cao, R., Hedlund, E.-M., Söll, I., Lundberg, J. O., Hauptmann, G., Steffensen, J. F., & Cao, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907608106 · Cited by 62
Self-citationPathological angiogenesis facilitates tumor cell dissemination and metastasis
Rouhi, P., Lee, S. L. C., Cao, Z., Hedlund, E., Jensen, L. D., & Cao, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.5.10853 · Cited by 61 · cited 1×
“At the primary tumor site, tumor invasion and metastasis are initiated at the early stage of tumor development by both the intrinsic genetic features of malignant cells and alterations in the tumor microenvironment (31).”
BackgroundSelf-citationAlbrecht, I., Kopfstein, L., Strittmatter, K., Schomber, T., Falkevall, A., Hagberg, C. E., Lorentz, P., Jeltsch, M., Alitalo, K. K., Eriksson, U., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014109 · Cited by 60 · cited 2×
“However, later studies do not support these claims, and opposing results that VEGF-B inhibits tumor angiogenesis have been reported (20, 21).”
ResultSchomber, T., Kopfstein, L., Djonov, V., Albrecht, I., Baeriswyl, V., Strittmatter, K., & Christofori, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1034 · Cited by 52
Cited by
Qiu, M., Wang, D., Liang, W., Liu, L., Zhang, Y., Chen, X., Sang, D. K., Xing, C., Li, Z., Dong, B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714421115 · Cited by 812
Self-citationMolecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1366 · Cited by 481
Chiang, S. P. H., Cabrera, R. M., & Segall, J. E. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00238.2015 · Cited by 311
Specific Gut Microbiome Signature Predicts the Early-Stage Lung Cancer
Zheng, Y., Fang, Z., Xue, Y., Zhang, J., Zhu, J., Gao, R., Yao, S., Ye, Y., Wang, S., Lin, C., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1737487 · Cited by 301
Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
Iwamoto, H., Abe, M., Yang, Y., Cui, D., Seki, T., Nakamura, M., Hosaka, K., Lim, S., Wu, J., He, X., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.005 · Cited by 300
Self-citation
Metadata
- Authors
- Yang, X., Zhang, Y., Hosaka, K., Andersson, P., Wang, J., Tholander, F., Cao, Z., Morikawa, H., Tegnér, J., Yang, Y., Iwamoto, H., Lim, S., & Cao, Y.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-05-19
- Volume
- 112
- Issue
- 22
- Pages
- E2900-9
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1511190501
- Cited by
- 161
- References
- 42
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.